Detection of circulating prostate cells by reverse transcriptase-polymerase chain reaction of human glandular kallikrein (hK2) and prostate-specific antigen (PSA) messages. 1997

E Corey, and E W Arfman, and M M Oswin, and S W Melchior, and D J Tindall, and C Y Young, and W J Ellis, and R L Vessella
Urology Department, School of Medicine, University of Washington, Seattle 98195, USA.

OBJECTIVE To investigate the clinical value of human glandular kallikrein (hK2) reverse transcriptase-polymerase chain reaction (RT-PCR) for detection of prostate cells in circulation and to compare the results with those obtained from prostate-specific antigen (PSA) RT-PCR. METHODS We examined peripheral blood (PB) and bone marrow (BM) samples of 13 patients with advanced-stage prostate cancer and 63 patients with clinically localized disease for the presence of circulating prostate cells. An RT-PCR protocol with a two-step amplification cycle and hot-start conditions was used. RESULTS The limit of detection of the PCR portion is similar for PSA and hK2 (5 to 10 copies of the plasmid containing the cDNA). The RT-PCR limit of detection is one LNCaP cell in 10(8) peripheral blood mononuclear cells (PMBC) for PSA, and one LNCaP cell in 10(7) PMBC for hK2. Of the BM samples obtained prior to radical prostatectomy, 71.4% were positive for PSA mRNA and 41.3% were positive for hK2 mRNA. In PB, the PSA positivity was 19% and hK2 positivity 12.7%. In advanced-stage patients, there were 76.9% PSA-positive samples in BM versus 38.5% hK2-positive samples; 46.2% of patients were positive in PB for PSA versus 30.8% for hK2. CONCLUSIONS We have developed a sensitive RT-PCR protocol for detection of hK2 mRNA and evaluated the suitability of hK2 mRNA in comparison with PSA mRNA as an additional marker for detection of prostate cells in circulation. Combining results of these two tests increased the sensitivity of detection.

UI MeSH Term Description Entries
D007610 Kallikreins Proteolytic enzymes from the serine endopeptidase family found in normal blood and urine. Specifically, Kallikreins are potent vasodilators and hypotensives and increase vascular permeability and affect smooth muscle. They act as infertility agents in men. Three forms are recognized, PLASMA KALLIKREIN (EC 3.4.21.34), TISSUE KALLIKREIN (EC 3.4.21.35), and PROSTATE-SPECIFIC ANTIGEN (EC 3.4.21.77). Kallikrein,Kininogenase,Callicrein,Dilminal,Kallidinogenase,Kalliginogenase,Kallikrein A,Kallikrein B',Kallikrein Light Chain,Kinin-Forming Enzyme,Padutin,alpha-Kallikrein,beta-Kallikrein,beta-Kallikrein B,Enzyme, Kinin-Forming,Kinin Forming Enzyme,Light Chain, Kallikrein,alpha Kallikrein,beta Kallikrein,beta Kallikrein B
D008297 Male Males
D009360 Neoplastic Cells, Circulating Exfoliate neoplastic cells circulating in the blood and associated with metastasizing tumors. Circulating Neoplastic Cells,Embolic Tumor Cells,Embolism, Tumor,Neoplasm Circulating Cells,Tumor Cells, Embolic,Cells, Neoplasm Circulating,Circulating Cells, Neoplasm,Circulating Tumor Cells,Cell, Circulating Neoplastic,Cell, Circulating Tumor,Cell, Embolic Tumor,Cell, Neoplasm Circulating,Cells, Circulating Neoplastic,Cells, Circulating Tumor,Cells, Embolic Tumor,Circulating Neoplastic Cell,Circulating Tumor Cell,Embolic Tumor Cell,Embolisms, Tumor,Neoplasm Circulating Cell,Neoplastic Cell, Circulating,Tumor Cell, Circulating,Tumor Cell, Embolic,Tumor Cells, Circulating,Tumor Embolism,Tumor Embolisms
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012333 RNA, Messenger RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm. Messenger RNA,Messenger RNA, Polyadenylated,Poly(A) Tail,Poly(A)+ RNA,Poly(A)+ mRNA,RNA, Messenger, Polyadenylated,RNA, Polyadenylated,mRNA,mRNA, Non-Polyadenylated,mRNA, Polyadenylated,Non-Polyadenylated mRNA,Poly(A) RNA,Polyadenylated mRNA,Non Polyadenylated mRNA,Polyadenylated Messenger RNA,Polyadenylated RNA,RNA, Polyadenylated Messenger,mRNA, Non Polyadenylated
D016133 Polymerase Chain Reaction In vitro method for producing large amounts of specific DNA or RNA fragments of defined length and sequence from small amounts of short oligonucleotide flanking sequences (primers). The essential steps include thermal denaturation of the double-stranded target molecules, annealing of the primers to their complementary sequences, and extension of the annealed primers by enzymatic synthesis with DNA polymerase. The reaction is efficient, specific, and extremely sensitive. Uses for the reaction include disease diagnosis, detection of difficult-to-isolate pathogens, mutation analysis, genetic testing, DNA sequencing, and analyzing evolutionary relationships. Anchored PCR,Inverse PCR,Nested PCR,PCR,Anchored Polymerase Chain Reaction,Inverse Polymerase Chain Reaction,Nested Polymerase Chain Reaction,PCR, Anchored,PCR, Inverse,PCR, Nested,Polymerase Chain Reactions,Reaction, Polymerase Chain,Reactions, Polymerase Chain
D017430 Prostate-Specific Antigen A glycoprotein that is a kallikrein-like serine proteinase and an esterase, produced by epithelial cells of both normal and malignant prostate tissue. It is an important marker for the diagnosis of prostate cancer. Kallikrein hK3,gamma-Seminoprotein,hK3 Kallikrein,Prostate Specific Antigen,Semenogelase,Seminin,Kallikrein, hK3,gamma Seminoprotein
D020840 Tissue Kallikreins A family of trypsin-like SERINE ENDOPEPTIDASES that are expressed in a variety of cell types including human prostate epithelial cells. They are formed from tissue prokallikrein by action with TRYPSIN. They are highly similar to PROSTATE-SPECIFIC ANTIGEN. Human Glandular Kallikrein 1,Human Glandular Kallikrein 2,Human Glandular Kallikreins,Pancreatic Kallikrein,Urinary Kallikrein,hK1 Kallikrein,hK2 Kallikrein,Glandular Kallikrein,Glandular Kallikrein-1,Kallikrein 1,Kallikrein 2,Prostate Specific Kallikrein,Tissue Kallikrein,Glandular Kallikrein 1,Glandular Kallikreins, Human,Kallikrein, Glandular,Kallikrein, Pancreatic,Kallikrein, Prostate Specific,Kallikrein, Tissue,Kallikrein, Urinary,Kallikrein, hK1,Kallikrein, hK2,Kallikrein-1, Glandular,Kallikreins, Human Glandular,Kallikreins, Tissue,Specific Kallikrein, Prostate

Related Publications

E Corey, and E W Arfman, and M M Oswin, and S W Melchior, and D J Tindall, and C Y Young, and W J Ellis, and R L Vessella
January 1995, Urologic oncology,
E Corey, and E W Arfman, and M M Oswin, and S W Melchior, and D J Tindall, and C Y Young, and W J Ellis, and R L Vessella
December 2000, Cancer research,
E Corey, and E W Arfman, and M M Oswin, and S W Melchior, and D J Tindall, and C Y Young, and W J Ellis, and R L Vessella
January 1998, Methods in molecular medicine,
E Corey, and E W Arfman, and M M Oswin, and S W Melchior, and D J Tindall, and C Y Young, and W J Ellis, and R L Vessella
July 1997, Clinical biochemistry,
E Corey, and E W Arfman, and M M Oswin, and S W Melchior, and D J Tindall, and C Y Young, and W J Ellis, and R L Vessella
September 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
E Corey, and E W Arfman, and M M Oswin, and S W Melchior, and D J Tindall, and C Y Young, and W J Ellis, and R L Vessella
January 2005, International journal of cancer,
E Corey, and E W Arfman, and M M Oswin, and S W Melchior, and D J Tindall, and C Y Young, and W J Ellis, and R L Vessella
October 2000, British journal of cancer,
E Corey, and E W Arfman, and M M Oswin, and S W Melchior, and D J Tindall, and C Y Young, and W J Ellis, and R L Vessella
March 1999, Prostate cancer and prostatic diseases,
E Corey, and E W Arfman, and M M Oswin, and S W Melchior, and D J Tindall, and C Y Young, and W J Ellis, and R L Vessella
January 1997, Annales de dermatologie et de venereologie,
E Corey, and E W Arfman, and M M Oswin, and S W Melchior, and D J Tindall, and C Y Young, and W J Ellis, and R L Vessella
April 1999, The Journal of urology,
Copied contents to your clipboard!